HC Wainwright & Co. Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $600
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and raised the price target from $500 to $600.
August 05, 2024 | 7:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has maintained a Buy rating on Vertex Pharmaceuticals and raised the price target from $500 to $600.
The raised price target and maintained Buy rating from a reputable analyst firm is likely to positively impact Vertex Pharmaceuticals' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100